Johnson & Johnson Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
Johnson & Johnson (JNJ) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of 0.00% for the 12-month period ending 2011-01-02, per its 10-K filed 2011-02-25.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2011-02-25
- Johnson & Johnson effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2011 was 0.00%.
- Johnson & Johnson effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2010 was 0.00%, a 100.00% decline from fiscal 2008.
- Johnson & Johnson effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2008 was 0.40%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|
| 2011-01-02 | 0.00% 10-K · filed 2011-02-25 |
| 2010-01-03 | 0.00% 10-K · filed 2011-02-25 |
| 2008-12-28 | 0.40% 10-K · filed 2011-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |